Influence of hydroxychloroquine on the bioavailability of oral metoprolol
- 1 June 2000
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 49 (6), 549-554
- https://doi.org/10.1046/j.1365-2125.2000.00197.x
Abstract
Aims Hydroxychloroquine (HCQ) is used widely in the treatment of chronic inflammatory diseases such as rheumatoid arthritis. Since there is great interindividual variability in the pharmacokinetics of HCQ and chloroquine is a potent inhibitor of CYP2D6-catalysed pathways in vitro, we wished to study the interaction of HCQ with CYP2D6-mediated metabolism of other drugs in vivo. Methods Metoprolol and dextromethorphan (DM) were selected as probe drugs because they are well-studied and widely used test substrates of CYP2D6. In this randomized, double-blind crossover study, seven healthy volunteers with extensive metabolizer phenotype for CYP2D6 ingested either 400 mg hydroxychloroquine or placebo daily for 8 days after which single oral dose pharmacokinetics of metoprolol were investigated. Dextromethorphan metabolic ratio (DM-MR) was also determined at baseline and after the ingestion of HCQ or placebo. Results Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 ± 4.6%) and maximal plasma concentrations (72 ± 6.9%) of metoprolol. While the DM-MR values were not significantly changed, the phenotypic classification of one individual, who was heterozygous for a mutant CYP2D6 allele, was converted to a poor metabolizer by HCQ administration. Conclusions HCQ inhibits metoprolol metabolism most probably by inhibiting its biotransformation by CYP2D6. The inhibitory effect of HCQ on dextromethorphan metabolism was not apparent when DM-MR was used as an indicator, except in an individual with limited CYP2D6 capacity.This publication has 37 references indexed in Scilit:
- CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotypeBritish Journal of Clinical Pharmacology, 1999
- Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3AJournal of Pharmacy and Pharmacology, 1998
- Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolutionPharmacogenetics, 1997
- Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S‐mephenytoin (CYP2C19) hydroxylation phenotypesBritish Journal of Clinical Pharmacology, 1996
- Geographical/Interracial Differences in Polymorphic Drug OxidationClinical Pharmacokinetics, 1995
- Clinical Pharmacokinetics of Slow-Acting Antirheumatic DrugsClinical Pharmacokinetics, 1993
- Prevention of Chloroquine Absorption by Activated CharcoalHuman & Experimental Toxicology, 1992
- Inhibition of Metoprolol Metabolism by Chloroquine and other Antimalarial Drugs*Journal of Pharmacy and Pharmacology, 1990
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and ResponseThe New England Journal of Medicine, 1982